Novartis AG researches, develops, manufactures, and markets healthcare products internationally. They offer prescription medicines in areas like cardiovascular, immunology, oncology, ophthalmology, and hematology. The company has agreements with Alnylam Pharmaceuticals and Dawn Health to develop and commercialize inclisiran and Ekiva respectively.
| Indicator | Value |
|---|---|
| PER | 20.5 |
| EV/EBITDA | 12.6 |
| Price/Free Cash Flow' | 17.8 |
| ROIC | 24.0% |
| Net Debt/EBITDA | 0.9 |